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The primary focus of national blood programs is the provision of a safe and adequate blood supply. This goal is dependent on
regular voluntary donations and a regulatory infrastructure that establishes and enforces standards for blood safety. Progress in ex
vivo expansion of blood cells from cell sources including peripheral blood, cord blood, induced pluripotent stem cells, and human
embryonic stem cell lines will likely make alternative transfusion products available for clinical use in the near future. Initially,
alloimmunized patients and individuals with rare blood types are most likely to beneﬁt from alternative products. However, in
developed nations voluntary blood donations are projected to be inadequate in the future as blood usage by individuals 60 years
and older increases. In developing nations economic and political challenges may impede progress in attaining self-suﬃciency.
Under these circumstances, ex vivo generated red cells may be needed to supplement the general blood supply.
1.Introduction
In the last 30 years, transfusion medicine has evolved from
a ﬁeld focused on blood component therapy and red blood
cell serology to include advanced cellular therapies produced
by ex vivo expansion [1, 2]. The broadest applications of
cellulartherapiestodatehavebeenintheareaofregenerative
medicine and have involved ex vivo cultured ﬁbroblasts, ke-
ratinocytes, and chondrocytes (reviewed in [3]), but sub-
stantial progress has also occurred with cellular therapies
involving lymphoid and hematopoietic cells. Infusions of
donor lymphoid cells to enhance engraftment following
allogeneicstemcelltransplantationisacommonpractice[4],
and progress has occurred in the development of adoptive
T-cell therapies and cellular vaccines [5, 6]. Sipuleucel-T, an
autologous cancer vaccine prepared from peripheral blood
mononuclear cells (PBMCs) that have been activated and
expanded ex vivo with a recombinant fusion protein con-
sisting of prostatic acid phosphatase fused to granulo-cyte-
macrophage colony-stimulating factor (GM-CSF), has been
licensed for treatment of castration-resistant prostate cancer
[6, 7]. Experimental therapies using ex vivo expanded cells
are also being evaluated to improve the results of umbilical
cord blood transplantation in adults [8, 9]. Infusion of
notch-mediated ex vivo expanded cord blood progenitors
shortens the time to neutrophil recovery [8] and infusion
of ex vivo expanded T regulatory cells appeared to decrease
the severity of acute graft versus host disease [9]. Substantial
progress has also occurred in developing culture systems for
exvivogenerationofredbloodcells[10–17].Thecellsources
under evaluation include peripheral blood mononuclear
cells (PBMCs), CD 34pos mobilized cells, cord blood (CB),
induced pluripotent stem cells (iPSCs) and human embry-
onic stem cell (hESC) lines [10–16]( Table 1).
The United States Department of Defense is supporting
research focused on ex vivo generation of red blood cells
from cord blood on an industrial scale. Arteriocyte, a bio-
technology company in Cleveland, Ohio, with a coalition
of academic and industrial scientists supported in part by
research funding from the United States Department of
Defense recently provided red cells generated from cord
blood to the United States Food and Drug Administration2 Stem Cells International
Table 1: Cell sources for ex vivo generation of red blood cells∗.
Cell type Source Special consent required Advantages Disadvantages
Peripheral blood
mononuclear cells
(PBMCs)
By product of
leukoreduction No Donor with known
phenotype Limited expansion capacity
Apheresis
collection Yes
≥3 products from
single collection
Donors may become
ineligible
Mobilizing agent
before apheresis
Yes (for mobilization and
apheresis)
Expansion similar to
cord blood with
humanized media
Quality control
requirement greater than
blood
Cord blood
Low volume units
unsuitable for
transplantation
Yes
Hematopoietic
progenitor cell
number > PBMC
3–50 products
phenotype must be
determined
Multiple donations not
possible
Quality control moderately
complex
iPSC
Fibroblast cultures
from autologous or
allogenic donors of
known phenotype
Y e s( f o rs k i nb i o p s y ,
ﬁbroblast culture, and
induction of
pluripotency)
Unlimited expansion
capacity
Quality control highly
complex
hESC
Human embryos
 1200 cell lines
available
Yes Unlimited expansion
capacity
Ethical limitations on
development and use
Quality control highly
complex
∗Bacterial, mycoplasma, fungal, or viral contamination possible.
(US FDA) for evaluation [ABC newsletter July 23, 2010]. On
March 8, 2011, Cellectis, a French biotechnology company,
announced StemRed a joint venture with Etablissement
Francais du Sang that will develop red cells ex vivo from
induced pluripotent stem (iPS) cells [http://www.dailymar-
kets.com/stock/2011/03/08/cellectis-and-the-etablissement-
francais-du-sang-launch-stemred-a-program-to-produce-
red-blood-cells-from-stem-cells/%5d.]. These eﬀorts to pro-
duce red blood cells in vitro using existing biotechnologies
recently led to the ﬁrst-in-man injection of ex vivo generated
red cells in an autologous situation [17].
Scientists studying ex vivo production of platelets have
refocused on animal models to clarify the optimal cell prod-
uct for transfusion, that is, megakaryocytes or mature
platelets [18] while eﬀorts continue to improve ex vivo
platelet production from umbilical cord blood hematopoi-
etic progenitors using immobilized glycosaminoglycans to
enhance megakaryocyte progenitor expansion and platelet
releasefromCD41apos megakaryocyteprogenitorsinvitroby
inhibiting megakaryocyte apoptosis [19].
Eﬀorts to generate neutrophils are also continuing,
perhaps encouraged in part by clinical trials to determine
if larger doses of granulocytes collected by apheresis from
donors stimulated with dexamethasone and granulocyte
colony stimulating factor (G-CSF) would improve clinical
outcomes in neutropenic patients with sepsis [20–22]. In
this regard it is important to note that a Phase I/II trial
sponsored by Cellerant Therapeutics and the Department
of Health and Human Services is evaluating the safety,
tolerability, and activity of ex vivo expanded human myeloid
progenitor cells (CLT-008) administered after up to 5
days of “standard of care” cytarabine-based consolida-
tion chemotherapy in acute lymphoblastic leukemia, acute
myeloid leukemia, and high-risk myelodysplasia [http://clin-
icaltrials.gov/ct2/show/NCT01297543]. Given the enormous
eﬀort currently focused on ex vivo expansion of blood cells
in general and the progress in ex vivo expansion of red blood
cells in particular, the potential clinical beneﬁts to be derived
from such alternative products should be considered.
2.MaterialsandMethods
The authors conducted searches on PubMed and Google
using the following search terms: adverse reactions, allergic
transfusion reactions, alloimmunization, blood group anti-
gens, blood safety, blood supply, blood collection, blood
donors, blood transfusion, developing countries, developed
countries, emerging diseases, HLA antigens, hemovigilance,
history of blood transfusion, neutrophil-speciﬁc antigens,
platelet-speciﬁc antigens, transfusion medicine, transfusion
medicine research, clinical trials, transfusion related acute
lung injury, and transfusion-transmitted infections. In ad-
dition the following websites were consulted: European
Medicines Association (EMEA), World Health Organization,
United States Department of Health and Human Services
Committee on Blood Safety and Availability, Centers for
Blood Evaluation and Research, US FDA, Serious Hazards
of Transfusion (SHOT). Consensus on needs in transfusion
medicine was developed by a process that involved expert
opinion as presented in the scientiﬁc literature, positionStem Cells International 3
papers and statements by governmental and non-govern-
mental organizations involved in areas of blood safety and
availability, and discussions among the authors.
3. Results
3.1. Perspective on Needs in Transfusion Medicine. Since the
beginning of modern transfusion therapy extraordinary
eﬀorts have been required to maintain a safe and adequate
blood supply [23–25]. Governments have acknowledged the
importance of these eﬀorts to the overall public health by
supporting the development of national blood programs
and creating administrative and regulatory structures to
assure the health of blood donors and the safety of blood
products [26–28]. The goal for nations has been to attain
national self-suﬃciency, a target that may be unobtainable
for some nations with the current economic, political,
and social challenges. For more than a decade eﬀorts to
develop national blood programs were supported by the
World Health Organization (WHO) Global Collaboration
on Blood Safety, a voluntary partnership of internationally
recognized organizations with expertise in various aspects of
transfusion medicine [29]. WHO emphasized ﬁve important
strategies considered critical to the development of eﬀective
national blood programs. These were recently reiterated in
a forum addressing the role of regulatory agencies [27]:
(1) “establishment of well-organized, nationally coordinated
blood transfusion services with legislation and eﬀective
mechanisms for oversight, to ensure the timely availability
of safe blood and blood products for all patients requiring
transfusion,” (2) “collection of blood from voluntary non-
remunerated blood donors from low risk populations,”
(3) “performing testing for (a) transfusion-transmissible
diseases[includingHIV,hepatitisB,hepatitisC,andsyphilis]
(b) major blood groups and (c) blood compatibility,” (4)
“safe and appropriate use of blood and a reduction in
unnecessary transfusions,” and (5) “quality systems covering
theentiretransfusionprocess,fromdonorrecruitmenttothe
follow-up of the recipients of transfusion.” Alignment of a
safe and adequate blood supply with achievement of speciﬁc
WHO Millennium Development Goals (MDGs) assisted
developing nations in establishing priorities [30, 31]. The
blood supply impacts MDG 4 reduction of the underﬁve
child mortality rate by two-thirds, MDG5 reduction in the
maternal mortality rate by three-quarters, MDG 6A halting
and reversing the spread of HIV by assuring that younger
individuals have comprehensive correct information about
HIV and HIV prevention obtained at school and MDG6C
decreasing death rates associated with malaria, often caused
by severe anemia. The global economic crisis has required
that WHO reassess priorities, and The International Society
for Blood Transfusion (ISBT) has established the ISBT
Working Party on Global Blood Safety to continue the work
begun by the WHO [32].
Adverse reactions following blood transfusion that
could not have been predicted based on current scientiﬁc
knowledge have been a concern throughout the history of
transfusion medicine [23–25]. Prevention of transfusion-
transmitted infections [33–38] and characterization of
human blood groups to assure transfusion of compatible
blood products [39–43] have always been priorities, but
adverse reactions following transfusion continue to occur
despite scientiﬁc and technical advances and regulatory har-
monization[44–50].Risksposedbynewandemerginginfec-
tions increase [51–53], and evolving scientiﬁc knowledge
about the immunologic and physiologic consequences of
transfusion [54–59] make the descriptors safe and adequate
moving targets.
3.2.TheBloodSupply. Indevelopednationsthebloodsupply
is adequate overall [60–62], but extreme weather conditions
and natural disasters such as the recent earthquake and
tsunami in Japan and ﬂooding in the United States disrupt
routine blood collection activities leading to temporary
shortages. The WHO 2008 Blood Safety Survey, which
included data from 164 nations representing 92% of the
global population, reported on 91.8 million donations.
Forty-eight percent of donations were collected in high-
income countries representing only 15% of the world pop-
ulation [63]. The accepted standard for evaluating blood
availability is blood donations per 1000-population. In this
report the donation rate for high-income countries was on
average 36.4 (range 13.3–64.6) donations/1000 population,
but the rate was lower in middle income and low income
nations: 11.6 (range 1.65–36.2)/1000 population and 2.8
(range 0.40–8.2)/1000 population on average, respectively.
While there have been substantial improvements in blood
safety as developing countries have implemented the WHO
recommended testing for syphilis, hepatitis B, hepatitis C,
and human immune deﬁciency virus (HIV), some countries
continue to rely on family/replacement and paid donors
(36% low income and 27% middle income, resp.) whereas
high-income countries reported only 0.3% of such donors.
The 2009 National Blood Collection and Utilization
SurveyReportprovidedinformationonbloodcollectionand
utilization in the United States for 2008 [61]. The whole
blood/red cell collection rate per thousand population was
85.8, and 14,855,000 units of red cells were transfused for
a transfusion rate of 48.8 units/1000 population. Bench-
marking data presented at a 2009 meeting of the Alliance of
BloodOperatorsindicatedthatfor2007/2008thetransfusion
rate was on average lower in the European Union (40/1000
on average, with rates in Germany and Denmark closer to
United States) and in Canada (32/1000) compared to the
United States (48-49/1000 population) [62]. The average
transfused dose of platelets was 5.8/1000 for the US, 4.3
for the National Health Service Blood and Transplant, and
4/1000 for France. Plasma supplies also appear to be
adequate although shortages of AB plasma and plasma from
IgA-deﬁcient donors are occasionally reported to be in short
supply. In 2006, 4,010,000 units of fresh frozen and apheresis
plasma were transfused in the United States with the
median volume of plasma for a single episode being 300mL.
Plasma is also collected for fractionation. There is growing
concern among patient advocacy groups that the amount
of plasma available for fractionation to produce coagulation
factor concentrate, intravenous immune globulin, and other
plasma products for rare diseases will be inadequate to meet4 Stem Cells International
clinical needs. Most nations permit only non-remunerated
blood and plasma collections whereas others (including
the United States) permit remunerated as well as non-
remunerated plasma donations. Patient advocacy groups
are concerned that eﬀorts to collect needed plasma from
paid donors may compromise donor standards and disrupt
routine blood collections. The issue of paid plasma donation
is reviewed elsewhere [64]. The Dublin Consensus Statement
summarizes these concerns [65]. Recombinant products
have been developed to replace some but not all therapeutic
plasma proteins. Movement of source plasma and recovered
plasma across borders is quite common and perhaps serves
as an example of how blood reserves could be shared across
borders with standardized regulatory and manufacturing
standards. While these data indicate that the blood supply
is adequate in developed countries at the present time, there
is growing concern that in the future the blood supply may
become inadequate [66–74].
Several factors are responsible for these concerns. Firstly,
the number of conditions for which donors are temporarily
or permanently deferred is increasing [48, 51–53, 64, 66].
Globalization and emerging infections are implicated in
many of these deferrals [33]. A study that estimated donor
eligibility in the US population using 31 exclusionary
factors corresponding to AABB standards concluded that
conventional methods overestimate eligible donor preva-
lence by approximately 59% [67]. In addition the aging
of the population is expected to impact blood availability
by increasing blood usage [68–73]. The world population,
currently estimated at 6.8 billion, is projected to reach 7
billion in 2012 and surpass 9 billion by 2050 [74]. Most of
the population increase (2.3 billion) will occur in developing
countries where individuals 15–59 years old will account for
1.2 billion and individuals 60 years and over will account
for 1.1 billion of the expected increase. The population
in developed countries is expected to increase from 1.23
billion to 1.28 billion. However, the worldwide population
of individuals of 65 years and over is projected by the US
Census bureau to increase from 7.7% (2010) to 16.5% in
2050. Blood donations will also be aﬀected by aging of the
population [68–80].
The American Red Cross reported that donations by
repeat donors 50 years or older increased from 22.1% of
total donations in 1996 to 34.5% of total donations in 2005
[80]. During the same period a decrease in the numbers
of male and female donors between 20 and 49 years of age
was observed. Data from Germany reﬂects similar donation
patterns in that repeat donors are more likely to belong to
older age groups (35–44 years and 45–54 years) [70, 71].
The issue of an aging donor base has been resolved in
part by countries such as the United States, the United
Kingdom, and Australia by eliminating the upper age limit
of 70 and allowing younger donors (16 years) to donate with
parental permission [75–79]. The Club 25 concept originally
developed in Zimbabwe [79]i sb e i n ga d a p t e df o ru s ei n
developed countries. Despite these eﬀorts, increased blood
usage by older populations remains an issue.
Most transfusions in older individuals are related to
diagnoses of cardiovascular disease, cancer, and the need for
orthopedic surgery [68, 69]. Investigators from the Finnish
Red Cross observed that many developed nations had similar
age-standardized mortality rates for cancer, cardiovascular
disease, injuries, and noncommunicable disease, and using
these data simulated red cell usage per 1000 population
between 2010 and 2050 for several developed countries
based on age-distributed variation in blood usage in Finland
between 2002 and 2006 [72]. The simulation predicted
substantial increases in blood usage in developed countries
associated with a decrease in the size of the population
eligible to donate. Earlier studies had predicted a shortfall
in blood collections in the United States [68]. Independent
assessments using alternative data sources conﬁrm the
projected increase in demand for blood caused by increases
in the population of individuals over 60 years of age [71, 73].
3.3. Prevention of Transfusion-Transmitted Infections: Global
Perspective. Progress in preventing transfusion-transmitted
infections was recently reviewed [35] Implementation of
restrictive donor eligibility criteria and use of volunteer
non-remunerated donors, along with speciﬁc testing for
syphilis and hepatitis B, hepatitis C, HIV1/2, and HTLV1/2,
are critical steps in assuring blood safety. In developing
countries recruitment of volunteer non-remunerated donors
is impacted by cultural deﬁnitions of community [81–
83] instead of geographic proximity. As a result, eﬀorts
to recruit volunteer donors in some nations have been
ineﬀective. Research conducted on the impact on blood
safety of converting family/replacement donors to allogeneic
donors in South Africa has demonstrated that when such
donors are repeat donors, the blood provided is safer than
ﬁrst-time volunteer donors [84–86]. These observations are
consistent with previous studies in developed countries
indicating a lower risk of infection for repeat donors and
should encourage more innovative approaches for donor
recruitment in Sub-Saharan Africa.
The most recent published data from the American Red
Cross (using NAT testing) indicate that the residual risk
per donated unit is 1:1,149,000 for HCV, 1:357,000 to
1:280,000 for HBV, and 1:1,467,000 for HIV [36]. By con-
trast, the estimated residual risk of transfusion-transmitted
HIV in a multinational collaborative study involving ﬁve
nations in Sub-Saharan Africa which used either an antibody
assay or combined p 24antigen/antibody assays reported a
residual risk for HIV of 34.1 per 1 million donations which
represents 1 in 29,000 donations [86]. In addition to these
traditional transfusion transmissible diseases for which all
donor blood should be tested, donors are also screened for
other diseases based on the geographic location, such as for
malaria (either by history or using antibody tests [87, 88])
and for local viral and parasitic diseases such as Chagas’
disease [89, 90], dengue [91, 92], West Nile virus, [93–95]
and chikungunya [96]. In addition, epidemic viral diseases
such as H1N1 and yellow fever must also be considered.
Asymptomatic healthy blood donors may also transmit
common viral infections which do not cause harm to the
average transfusion recipient but which may represent sig-
nificant risks in selected patient populations. For example,
latent cytomegalovirus infection (CMV) is common inStem Cells International 5
normal donors. Depending on the geographic location and
socioeconomic status of donors, 70–100% of donors may be
seropositive. Pregnant women, neonates, and other immu-
no-compromised CMV-negative patients may develop seri-
ous infectious complications due to transfusion-transmitted
CMV. Currently, leukoreduced blood products and products
from CMV seronegative donors are used for populations
vulnerable to CMV [97–101]. A meta-analysis comparing
leukoreduction and antibody screening as CMV prevention
strategies reported that both techniques were eﬀective in
reducing transmission but indicated that antibody screening
m a yb em o r ee ﬀective [98]. Studies of the natural course of
CMV infection in blood donors indicate that CMV DNA
may persist up to 269 days following infection [97, 99]a n d
suggest that blood donors who have recently seroconverted
be deferred for a year.
Parvovirus B19, an erythrotropic virus that uses the P
blood group antigen to infect erythroid progenitors, may
cause severe anemia, red cell aplasia, and congenital anoma-
lies when transmitted by transfusion [102–107]. Neonates,
pregnant women, and patients with congenital and acquired
forms of hemolytic anemia are most vulnerable to this
infection, but routine screening of blood donors for par-
vovirus B19 is not performed. However, plasma pools for
fractionation are screened for parvovirus B19 because cur-
rent fractionation/inactivation techniques do not completely
inactivate the virus and transmission of parvovirus by coag-
ulation factor concentrate is well documented. Although
the risk of transmission of parvovirus B19 appears low
in transfusion recipients because of preexisting protective
antibody from past natural infections in many transfusion
recipients and blood donors, transmission of parvovirus B19
by transfusion has been recently documented [103–105].
Data from the National Heart Lung and Blood Institute
Retrovirus Epidemiology Donor Study-II which tested pre-
and posttransfusion samples found no transmission to 24
susceptible recipients from transfusion of components with
parvovirus B19 DNA containing less than 106 IU/mL [102].
DatafromtheJapaneseRedCrosshemovigilancesystempro-
vide an alternative perspective which suggests that specially
screened products may be needed for selected populations
[104]. Between 1999 and 2008, when parvovirus B19 donor
screening was conducted using a cutoﬀ similar to that of
the REDS study, eight patients with transfusion transmitted
parvovirus B19 DNA were identiﬁed and sequence identity
between patient and the linked donor was conﬁrmed in 5
cases.Redcellaplasiadevelopedin3ofthe5conﬁrmedcases.
This report suggests that alternative blood products with
lower risk of parvovirus B19 infection should be provided
for at-risk patient populations.
3.4. Alloimmunization. As the scientiﬁc basis for producing
better and safer products for transfusion through donor
screening and product testing has made transfusion safer,
alloimmunization resulting from transfusion has emerged as
a major issue in clinical care. The magnitude of this problem
led to a recent NHLBI sponsored conference to identify areas
inwhichadditionalresearchwasneededtobetterunderstand
factors contributing to alloimmunization as well as research
on prevention and management of alloimmunization [108].
Alloimmunization in females may result from exposure to
paternal antigens during pregnancy. In the general popu-
lation alloimmunization occurs following transfusion, solid
organ or tissue transplantation, or following hematopoietic
stem cell transplantation with partially matched donors.
Blood contains many cells and proteins expressing poly-
morphic antigen systems that may lead to alloimmunization.
Erythrocytes alone may express antigens from 30 blood
group systems for which over 300 diﬀerent antigens have
been identiﬁed [40–43, 109–112]. Small numbers of residual
redcellsandleukocytesmaycontaminateplasmaandplatelet
products causing alloimmunization (anti-D developing fol-
lowingtransfusionofRhpositiveplasmatoRhnegativeindi-
vidualsoranti-HLAfollowingplatelettransfusion).Typically
blood products are matched for ABO group and Rh (D) only
unless patients are alloimmunized. Once alloimmunization
occurs subsequent transfusions must be matched unless the
antibody is considered clinically insigniﬁcant [112]. It is
estimated that 1–3% of the general population is immunized
to blood group antigens.
Alloimmunization is more common in chronically trans-
fused patients such as patients with hemoglobinopathies or
transfusion-dependent myelodysplasia [113–116]. Alloim-
munization also occurs more often in communities where
blood donors and blood recipients are from diﬀerent ethnic
groups [112]. Investigators observed that the rate of alloim-
munization in sickle cell disease (SCD) patients in Jamaica
where more blood donors were of African ancestry was
lower than the alloimmunization rate of SCD patients in the
UK where most blood donors were caucasian. Historically,
twenty- to thirty-ﬁve percent of chronically transfused
patientswithsicklecelldiseaseorthalassemiaareimmunized
to blood group antigens [113–116]. When these patients
experience a hemolytic transfusion reaction, autoantibodies
as well as alloantibodies to transfused cells may be produced,
causingasyndromereferredtoashyperhemolysis[117–121].
Limited matching strategies such as matching for Kell, Rh
(Cc, D, E, e), Fy, and Jk have reduced overall alloimmuniza-
tion rates in most chronically transfused patient populations
[113, 114] but have led to alloimmunization to variant blood
group antigen diﬀerences which testing with serological
reagents does not identify [122–125]. For example, in the
Blue Tag program at Children’s Hospital in Philadelphia,
established to identify African-American donors antigen-
matchedforAfricanAmericanpatientswithSCD,alloimmu-
nization to other more subtle antigen diﬀerences such as D-
deletion variants developed requiring more precise matching
with DNA-based technology [122]. Similar observations
have been made in other sickle cell patient populations
[123]. Patients with myelodysplasia and myeloproliferative
neoplasms may also require chronic transfusion support and
become alloimmunized. DNA-based methods are now being
used to screen large numbers of blood donors to identify
compatible blood for alloimmunized patients [126–137]. In
the United States, these methods are not FDA approved
and phenotypes are conﬁrmed with serological reagents.
While most of this work is occurring at blood centers, a
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may be able to identify some units in their existing inventory
[138].Identifyingmatchedbloodforpatientsalloimmunized
to multiple blood group antigens and patients with rare
blood types (variably deﬁned as 1/1000 or 1/10,000 or
fewer compatible donors) is a challenge. Although reference
laboratories around the world cooperate in this eﬀort [132],
bloodforsuchpatientsisofteninshortsupply.Bloodcenters
are now using information about rare blood types and the
populations most likely to contain compatible donors to
develop strategies to recruit such donors. For example, Life
Share Blood Centers (Louisiana, USA) has published on
its website statistics about the ethnicity of donors testing
negative for the blood group antigens S, s, and U (a high-
incidence antigen), a phenotype more common in African-
Americans than Caucasians. Publication of this data has
increased minority participation in blood donation. New
York Blood Center has a similar program to recruit donors
called Precise-Match, tailored for outreach to the various
ethnic groups in New York City.
Platelets express A and B blood group antigens, class I
HLA-A and HLA-B locus antigens (HLA-C locus antigens
are not expressed well on platelets), and platelet-speciﬁc
antigens 27 of which are well characterized [139–141].
Antibodies to HLA-A and HLA-B locus antigens are most
often implicated in platelet refractoriness, but antibodies
to platelet-speciﬁc antigens are also implicated [142, 143].
Neonatalthrombocytopeniausuallyinvolvesplatelet-speciﬁc
antigens(PLA1–17),butseveralcasesimplicatingantibodies
to HLA antigens have been described. Class I and or class
II HLA antigens are also expressed on various lymphocyte
and monocyte populations, and granulocytes express unique
polymorphic antigens [144, 145]. Plasma proteins also
express polymorphisms, but serious transfusion reactions
have been documented most often in IgA-deﬁcient and
haptoglobin-deﬁcient individuals who develop class-speciﬁc
antibodies to IgA and haptoglobin, respectively [146, 147].
Immunization to HLA antigens aﬀects not only survival
of transfused platelets but also prevents engraftment of
hematopoietic stem cells and may lead to allograft rejection
of solid organs as well as hematopoietic stem cells. Until
recently only alloimmunization of transfusion recipients
was thought to be a problem, but recently alloantibodies
to HLA and granulocyte antigens in donor plasma (and
apheresis platelets) have been documented to be the cause
of transfusion-related acute lung injury (TRALI) [140, 148].
B e c a u s ew o m e na r em o r el i k e l yt ob ea l l o i m m u n i z e d ,T R A L I
mitigation strategies include use of male donors, identiﬁ-
cation of never pregnant female donors, and identiﬁcation
of female donors testing negative for anti-HLA antibodies.
Implementation of this strategy has substantially reduced
morbidity and mortality from TRALI in developed countries
but has once again reduced the numbers of individuals
available to donate certain blood components.
Platelet transfusions have steadily increased over the past
eight years in developed countries. Transfusion of ABO
identical platelet products is preferred, but such products are
not always available. Platelet recovery in ABO-incompatible
transfusions may be slightly lower, but platelet survival is
normal. However, transfusion of ABO-nonidentical platelets
has caused serious hemolytic transfusion reactions in some
patients because of high-titer anti-A and anti-B in donor
plasma [149–153]. While hospitals have policies to manage
such transfusions, blood centers have not routinely per-
formed anti-A and anti-B titers to identify high-risk group
O donors. In Europe, blood centers are testing products and
restricting use to group O recipients (reviewed in [154]).
The use of platelet additive solutions on a large scale could
also lower the risk of hemolysis because such products
contain less plasma. A recent publication reported that de
novo HLA allosensitization in patients on ventricular assist
devices is lower when patients receive leukoreduced ABO
identical products, suggesting that even small amounts of
hemolysis might facilitate alloimmunization to HLA [151].
Thus matching both for ABO and HLA may be important
in providing transfusion support for highly alloimmunized
patients [155].
Refractoriness to platelet transfusion is usually caused by
alloimmunization to HLA antigens [142, 143, 155, 156]. The
TRAP study, a large randomized clinical trial designed to
compare leukoreduction and UVB irradiation in preventing
refractoriness to platelet transfusions related to alloimmu-
nization to HLA antigens, reported that 45% of AML
patients receiving control platelets but only 18% of patients
receiving leukoreduced and 21% of patients receiving UVB-
treated platelets were alloimmunized [156]. Following this
study, leukoreduced platelet products became the standard
of care even though UVB irradiation was also eﬀective.
Followup of patients who became alloimmunized to HLA
revealed that 56% of patients subsequently became antibody
negative [157]. Since UVB irradiation and riboﬂavin are
incorporated in current pathogen inactivation methods for
platelets, licensed in Europe but not yet in the US, there will
likely be renewed interest in this method to prevent alloim-
munization [158]. However, a meta-analysis of randomized
controlled trials of pathogen-reduced platelets indicates that
posttransfusion-corrected count increments were lower, an
observation that will aﬀect dosing strategies [159].
Granulocytes play a crucial role in protecting individuals
from a number of pathogens. In the early 1970s, the ﬁrst
studies suggesting that granulocyte transfusions might de-
crease mortality associated with bacterial infections were
published [160]. However, collection of adequate numbers
of granulocytes and provision of these products to patients
in a timely way is a logistical challenge. The introduction
of many new and more eﬀective antibiotics and antifungal
agents as well as the routine administration of G-CSF and
GM-CSF has substantially reduced mortality from infec-
tions. However, considerable mortality and morbidity still
occur in neutropenic patients following hematopoietic stem
cell transplantation. Clinical trials using granulocyte trans-
fusions have provided mixed results [161]. Currently gran-
ulocytes are collected by apheresis from prescreened donors
(often regular plateletpheresis donors) using dexamethasone
or a combination of dexamethasone and G-CSF and trans-
fused as soon as possible but never more than 24 hours
after collection. The logistics of collection, variable yields,
and limited information on the best conditions for storage
have contributed to the variable outcomes in clinical studiesStem Cells International 7
published to date. Alloimmunization to granulocyte-speciﬁc
antigens appears to inhibit the function of transfused gran-
ulocytes [160]. Three clinical centers have recently published
retrospective analyses of their experience with granulocyte
transfusions using optimal mobilization techniques and
reported improved survival [154, 162, 163]. An NHLBI-
sponsored phase III clinical trial examining the eﬀectiveness
of granulocyte transfusions in individuals with neutropenia
and infection following dose-intensive chemotherapy or
hematopoietic stem cell transplantation is underway [164].
Should this trial provide support for the eﬀectiveness of
granulocyte transfusions, a less labor-intense and more cost-
eﬃcientmethodtoproducegranulocyteswouldbedesirable.
3.5. The Red Cell Storage Lesion. Since the publication in
2008 by Koch et al. [55]o far e t r o s p e c t i v es t u d yr e p o r t i n g
increased risk of postoperative complications and reduced
short-term and long-term survival in cardiac surgery pa-
tients receiving blood stored for more than two weeks,
there has been considerable debate about the beneﬁts of
transfusing fresh versus older units of blood [57, 59, 165].
Biochemical changes during red cell storage in currently
licensed additive solutions are well documented. However,
the primary criteria for licensure are hemolysis (below 0.8%
in EU and 1% in the US) and red cell survival not less
than 75% at the end of storage [165, 166]. In an editorial
discussing the potential clinical relevance of this low level of
hemolysis on transfusion recipients, potential diﬀerences in
the eﬀects of free hemoglobin compared to hemoglobin in
microvesicles are discussed referencing studies of thrombin
generation by red cell supernatant [166]. It is not currently
known if clinical outcomes are aﬀected by the age of
blood transfused. However, a retrospective cohort study of
individuals in Sweden and Denmark transfused between
1995 and 2002 as recorded in the Scandinavian Donations
and Transfusions (SCANDAT) Database which analysed
404,959 transfusion episodes revealed a small (5%) excess
mortality for recipients of blood stored for 30–42 days and
mixed-age compared to recipients of blood stored for 10–19
days [167]. The authors noted no dose response pattern or
eﬀect of leukoreduction and concluded that the diﬀerences
observedwere“compatiblewithahigherbaselineriskamong
recipients of the very oldest units than with an actual
deleterious eﬀect of the oldest units.” However, should either
clinical or basic research studies provide conclusive evidence
that inferior outcomes are associated with transfusion of
blood stored for longer periods, the shift toward usage of
fresher blood would reduce blood inventories and create
signiﬁcant blood shortages.
The editorial by Simone A. Glynn, MD, MPH from the
Division of Blood Diseases and Resources at the National
Heart Lung and Blood Institute summarizes the situation
well by stating that, despite the numerous publications, there
is “genuine uncertainty as to whether transfusing fresher
blood is more, less, or equally beneﬁcial as transfusion
of older blood” [59]. The editorial identiﬁes four large
randomized clinical trials related to the age of transfused
blood that are underway in North America. The Canadian
Institutes of Health Research is funding two trials, one in
intensive care patients randomized to receive either less than
8-dayorstandardissueredbloodcells(2–42days)inTheAge
of Blood Evaluation (ABLE) Study which has as the primary
outcome 90-day all-cause mortality and a second study in
which premature infants (≤1250g) will be randomized to
receive either less than 8-day or 2–42-day aliquots with a
primary endpoint being a 90-day composite measure of
all cause mortality and organ dysfunction. The Cleveland
Clinic is conducting the Red Cell Storage and Outcomes in
Cardiac Surgery Trial (NCT00458783) in which individuals
18 yrs and older undergoing cardiopulmonary bypass for
primary and reoperative coronary artery bypass grafting,
coronary artery bypass grafting with a valve procedure,
and isolated valve procedures are randomized to receive
blood transfusion with storage duration less than 14 days
or greater than 20 days. NHLBI is also sponsoring through
the Transfusion Medicine Clinical Trials Group the Red Cell
Storage and Duration Study (RECESS)—NCT00991341 in
which individuals 12 years or older undergoing complex car-
diac surgery and likely to need transfusion are randomized
to receive blood ≤10 days storage duration or ≥21 days
storage duration. The primary outcome is the change in
the composite multiple organ dysfunction score (MODS).
Dr. Glynn also identiﬁed research projects funded under
the NHLBI program “Immunomodulatory, Inﬂammatory,
and Vasoregulatory Properties of Transfused Red Blood Cell
Units as a Function of Preparation and Storage” designed to
provide information on mechanisms via which transfusion
of older blood might lead to adverse physiological outcomes
and to design interventions to eliminate them. Current data
are inadequate to determine if transfusion of older units of
blood is associated with either short- or long-term adverse
outcomes. Basic research in animal models and prospective
randomized clinical trials are needed in this area.
3.6. Impact of Ex Vivo Generated Blood Cells on Needs in
Transfusion Medicine. Red blood cells have been successfully
generated ex vivo from peripheral blood mononuclear
cells, cord blood, and human-induced pluripotent stem cell
(hiPSC) and human embryonic stem cell (hESC) lines. The
expansion potential of cord blood and peripheral blood is
limited, but that of hiPSC and hESC is inﬁnite. Multiple
products from a single collection (blood or skin ﬁbroblasts)
would be generated from well-characterized donors under
GMP conditions. Irrespective of the cell source, the donor
will be selected to be negative for known transmissible
diseasesandwillrepresenteitherararephenotype(1/1000or
≤1/10,000) or a phenotype much in demand (O Rh negative
or O Rh positive). The primary product will be almost
devoid of other contaminating blood cells and suspended in
deﬁned media designed to support viability and cell function
but lacking immunoglobulins and other plasma components
which precipitate TRALI and allergic transfusion reactions
(IgA, haptoglobin). Theoretically, the equivalent of 10–50
therapeutic units of blood (2 × 1012 cells) can be generated
from a single cord blood unit. The development of cord
blood banks for hematopoietic stem cell transplantation has
created an infrastructure that facilitates collection of cord
blood for other uses (i.e., endothelial cells for regenerative8 Stem Cells International
medicine) [168]. Cord blood can also be cryopreserved
for up to 23 years with recovery of adequate numbers of
hematopoietic progenitors and the ability to generate iPS
[169]. Although the expansion potential of peripheral blood
is considered to be lower than that of cord blood, at present
peripheral blood is more readily obtained because it is a
byproduct of leukoreduction.
The ﬁrst in-man transfusion is likely to be from one of
these two cell sources with studies of red cells generated
from hESC or hiPSC coming later [170–172]. Currently
1200 hESC lines have been established worldwide, and 375
of these are deposited in two international registries [172].
Investigators at the forefront of ex vivo expansion studies
expect that GMP compliant facilities to produce red cells ex
vivo will be available within the next 2-3 years. Location of
manufacturing facilities will be critical given the complexity
of the manufacturing process and the need for reliable
transport. The potential impact of such products on blood
manufacturing operations is substantial.
The ﬁrst clinical use of ex vivo generated red cells is likely
to be for highly alloimmunized patients and for patients
with rare blood types [170, 171]. Theoretical calculations to
determine how many iPSC lines would be needed to support
alloimmunized patients in France have already been per-
formed [171]. Although a large number of embryonic stem
cell lines have been developed, the expression of blood group
antigens by erythrocytes from these cell lines is not known
[172]. Forty percent of rare units in France were provided to
patients with sickle cell anemia [171]. Data from WHO sug-
gests that worldwide patients with hemoglobinopathies are
represented among patients requiring chronic transfusion.
Hemoglobinopathies occur in over 332,000 conceptions or
births annually and account for 3.4% of under-5 mortality
[173, 174]. Worldwide an estimated 275,000 have a sickle
cell disorder and 56,000 a major thalassaemia, approximately
30,000 of which will require chronic transfusion to sur-
vive. In the WHO America region, 52.4% of transfusion-
dependent patients receive transfusions, but in the Eastern
Mediterranean region and South-East Asian region, which
have a higher number of transfusion-dependent patients,
17.8% and 9.6%, respectively, of transfusion-dependent
patients received transfusions [174]. These data suggest that,
as healthcare improves in developing nations, the number
of patients with hemoglobinopathies requiring transfusions
will increase and these individuals will likely need special
antigen-matched products.
Once manufacturing facilities are established for ex vivo
generationofredcells,thegeneralinventoryofbloodinboth
developing and developed countries could be increased by
ex vivo generation of red cells. Theoretically, if peripheral
blood mononucleated cells (PBMCs) from each whole blood
donation were to be expanded ex vivo, each donation
would produce not only one but possibly 3–10 or more
units of blood. This would allow blood donors to donate
less often, decrease concerns about iron deﬁciency, and
reduce costs for donor recruitment. PBMC generated by
leukoreduction during the manufacturing process for red
cells are the easiest product to obtain. The least expensive
way to prepare leukoreduced products is the buﬀyc o a t
method,butrecoveryofPBMCfromin-lineorsteriledocked
ﬁlters is also possible. In 2006, prestorage leukoreduction
was performed on approximately 11.3 million units of red
blood cells in the United States. Currently, cord blood units
are being collected as a source of hematopoietic progenitor
cells for transplantation, but cord blood contains other cell
populations that have value in regenerative medicine such
as na¨ ıve immune cells, mesenchymal cells, and endothelial
progenitor cells. Accurate ﬁgures for donations to public
banks are available. Donation rates to public banks vary
from 0.1% of births to 0.34% of births [168]. Some families
choose to bank cord blood for autologous/family use, and
these units are not available for ex vivo generation of blood
cells. Overall, these data indicate that a potentially vast
but untapped resource is available for ex vivo generation
of blood cells. At present there is no data to suggest that
ex vivo products are needed in developed nations for the
general inventory but should projections about increased
blood usage in individuals age 60 years and older be correct
such products may be needed in the future.
The supply of safe blood in developing countries has
improved in recent years but is still inadequate. Anemia
relatedtotrauma,pregnancy,ormalariaisthemostcommon
indication for transfusion, and currently blood is not always
available when needed. It is unrealistic to propose that a
countrythatcannoteﬀectivelyrunanationalbloodprogram
would have the resources to expand blood cells ex vivo.
However,amanufacturedbloodproductproducedelsewhere
could be imported. Manufactured products are more uni-
form because methods and product speciﬁcations can be
standardized with quality monitoring implemented to assure
that such standards are met. Under these circumstances,
cellular products might move freely across national borders
as is the case with some pharmaceuticals. Alternatively, one
mightmaintainthecurrentnot-for-proﬁtbusinessmodelfor
wholebloodcollectionandmodelexvivoexpansiononafor-
proﬁt model where economies of scale might work to reduce
overall cost.
Progress in ex vivo generation of megakaryocytes and
platelets is not as advanced as development of red cells.
The value of platelet transfusions in preventing hemorrhage
in thrombocytopenic patients and patients with throm-
bocythemia is not disputed although the level at which
platelet transfusions should be given prophylactically to
thrombocytopenic patients to prevent hemorrhage was the
subject of recent clinical trials. Platelets may be manu-
factured from whole blood by centrifugation to produce
platelet concentrate or prepared by apheresis. An adult
dose of platelets would require pooling of 4–6 units of
platelets depending on local practice or a single apheresis
product. Both products are usually leukoreduced. There is
ongoing concern about the adequacy of platelet inventories
for two reasons, the shelf life is short (maximum of 5
days) and platelet products stored at room temperature
are more likely to be contaminated with bacteria [37, 38].
Refractoriness to platelet transfusions is usually caused by
anti-HLA antibodies. Antibodies to platelet-speciﬁc antigens
may also be implicated. In neonatal thrombocytopenic
purpura, the oﬀending antibody is typically directed atStem Cells International 9
platelet-speciﬁc antigens. Refractoriness to platelet transfu-
sions is a signiﬁcant problem for multitransfused patients
with hematologic malignancies receiving chemotherapy or
undergoing hematopoietic stem cell transplantation. Iden-
tiﬁcation of suitable products for alloimmunized patients
involves HLA typing of the patient (typically performed
with DNA-based techniques), antibody screening for anti-
HLA class I and anti-platelet-speciﬁc antibodies (solid phase
or ﬂow cytometry) as well as platelet crossmatching (solid
phase or ﬂow cytometric techniques). Complex computer
algorithms for selecting HLA compatible donors based on
epitope sharing have been developed to identify compatible
products [142, 143]. Thus the ability to generate platelet
products ex vivo and platelet products lacking HLA antigens
inserumfree media wouldhave greatclinical value. Methods
have been developed to generate platelets ex vivo from cord
blood CD34 positive cells and from embryonic stem cells
[175]. Ex vivo generation of platelet products deﬁcient in
HLA class I antigen expression could have an enormous
impact on the provision of platelet products to refrac-
tory patients. Using an RNA-interference-based mechanism
( R N A i )i nw h i c hal e n t i v i r a lv e c t o rw a su s e dt oe x p r e s s
short-hairpin RNA targeting β2-microglobulin transcripts
in CD34 positive cells, Figueiredo et al. generated platelets
demonstrating an 85% reduction in class I HLA antigens
compared with platelets generated in CD34 positive cells
transduced with a lentiviral vector containing a nonsense
shRNA [175]. These platelets appeared to have normal func-
tion in vitro. Alternatively, hESC or hiPSC could be used to
generate products for highly immunized patients.
Granulocyte transfusions have not consistently demon-
strated improved clinical outcomes in infected neutropenic
patients. However, these inconsistent results may reﬂect
heterogeneity in patient populations, failure to transfuse an
adequate number of granulocytes, limited information on
optimal storage conditions for granulocyte products, and
diﬃculty in identifying a rapid reliable assay for determin-
ing granulocyte compatibility (other than ABO). Studies of
ex vivo generated neutrophils may provide valuable infor-
mation on optimal storage conditions for neutrophils and
may ultimately produce a product with a longer shelf-
life.
Theoretically, ex vivo generated red blood cells will be
produced on demand on a predictable schedule, will provide
cellular products of more uniform composition with limited
contamination by other cell types, will be associated with
lowerrates oftransmission of infectious diseases, causefewer
allergic reactions, produce a lower rate of alloimmunization
because extended matching will be possible, and will have
longer in vivo survival while producing less iron overload
than currently available products. It is not possible to predict
when these products will be approved for clinical use. Many
complex issuesrelated to scale-up production and the poten-
tial immunogenicity (neoantigen formation) of products
produced in vitro remain to be resolved. However, the
development of these products will inform and transform
quality control and manufacturing processes for traditional
blood products.
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